Claims
- 1. A compound of the formula I
- 2. The compound as defined in claim 1 wherein
Xa is 724wherein Q1 and Q2 are each independently a cycloalkyl, heterocyclic, aryl or heteroaryl ring, wherein Q1 may be substituted with 1 to four substituents selected from the group consisting of Ra and Rb, and Q2 may be substituted with 1 to four substituents selected from the group consisting of Ra, Rb and Q3; Q3 is a 3 to 8 membered fused or spiral cycloalkyl, heterocyclic, aryl or heteroaryl ring, wherein Q4 may optionally be substituted with 1 to 5 substituents selected from the group consisting of Ra, Rb and Q4; and Q4 is a 3 to 8 membered fused or spiral cycloalkyl, heterocyclic, aryl or heteroaryl ring, wherein Q4 may optionally be substituted with 1 to 5 substituents selected from the group consisting of Ra and Rb; A is N or CR11; B is N or CR11; and R11 is H or a bond.
- 3. The compound as defined in claim 1 wherein Xa has the structure
- 4. The compound as defined in claim 1 wherein Xa has the structure
- 5. The compound as defined in claim 2 wherein when Ra or Rb are R9, R6 is heterocycle or alkyl, optionally substituted with hydroxyl or halogen.
- 6. The compound as defined in claim 5 wherein R9 is (CH2)pC(O)OR6, (CH2)pOC(O)R6, or (CH2)pOC(O)N(R6)(CH2)mOH.
- 7. The compound as defined in claim 2 wherein when Ra or Rb are R9, R6 and R6′ are independently hydrogen, alkyl, or cycloalkyl, where the alkyl or cycloalkyl is optionally substituted with —C(O)OR7 or —C(O)NR5R5′, or R6 and R6′ taken together can be cyclized to form —(CH2)qX(CH2)s—.
- 8. The compound as defined in claim 7 wherein R9 is —(CH2)pN(R6)C(O)OR6′, —(CH2)pN(R6)C(O)NR6R6′, or (CH2)pOC(O)N R6R6′, where R6 and R6′ are independently hydrogen or alkyl, where the alkyl is optionally substituted with —C(O)NR5R5′, where R5 and R5′ are independently hydrogen or alkyl.
- 9. The compound as defined in claim 1 wherein the compound has the structure:
- 10. The compound as defined in claim 1 wherein the compound has the structure:
- 11. A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable carrier therefor.
- 12. The pharmaceutical composition of claim 9 further comprising at least one additional therapeutic agent selected from the group consisting of other compounds of formula I, parathyroid hormone, bisphosphonates, estrogen, testosterone, selective estrogen receptor modulators, selective androgen receptor modulators, progestin receptor agonists, anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-osteoporosis agents, anti-obesity agents, cardiac glycosides, cholesterol lowering agents and thyroid mimetics.
- 13. A method for increasing levels of endogenous growth hormone, which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof.
- 14. A method for treating or delaying the progression or onset of HIV wasting syndrome, muscular atrophy, lipodistrophy, long term critical illness, osteoporosis, sarcopenia, fraility or ARFD in the elderly, obesity, renal disease, anorexia, sleep disorders, depression, Syndrome X, diabetes, congestive heart failure, cardiac myopathy, cardiac dysfunction associated with valvular disease and cachexia which comprises administering to a mammalian patient in need of treatment a therapeutically effective amount of a compound as defined in claim 1.
- 15. The method according to claim 12 further comprising administering, concurrently or sequentially, a therapeutically effective amount of at least one additional therapeutic agent selected from the group consisting of other compounds of formula I, parathyroid hormone, bisphosphonates, estrogen, testosterone, selective estrogen receptor modulators, selective androgen receptor modulators, progestin receptor agonists, anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-osteoporosis agents, anti-obesity agents, cardiac glycosides, cholesterol lowering agents and thyroid mimetics.
- 16. A method for stimulating wound healing and/or the immune system which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof.
- 17. A method for increasing muscle mass and/or strength or maintaining muscle strength and function in the elderly which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof.
- 18. A method of increasing lean body mass which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof.
- 19. A method for improving cognitive function which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof.
- 20. A method for improving the immune response to vaccination which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof.
- 21. A method for accelerating the recovery of hip fracture which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof.
- 22. The pharmaceutical composition of claim 9 further comprising at least one nutritional supplement.
RELATED APPLICATIONS
[0001] This application claims priority benefit under Title 35 § 119(e) of United States provisional Application Nos. 60/408,099, filed Sep. 4, 2002, and 60/491,645, filed Jul. 31, 2003, the contents of which are herein incorporated by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60408099 |
Sep 2002 |
US |
|
60491645 |
Jul 2003 |
US |